The aim of this study was to investigate the radiopharmaceutical potential of N-(2,6-diisopropylphenyl)-N’- [4-(N,N-dimethylaminophenyl)]-perylene-3,4,9,10-tetra carboxylic diimide (DMANPER) radiolabeled with 131I using scintigraphic imaging and biodistributional techniques. Radiolabeled DMANPER (131I-DMANPER) was intravenously injected into an adult male Albino rabbit via its ear vein anesthetizing with a mixture of Alfazyne and Alfamine (Serva) to determine dynamic and static situations of radiolabeled compound in the rabbit metabolism. Three rats were used for biodistribution studies corresponding to different time intervals. The animals were sacrificed by heart puncture under ether anesthesia within post-injection time intervals ranging from 30 to 300 min. Results were expressed as % of the injected dose per gram tissue (% ID/g). TLRC analysis showed that DMANPER was successfully radioiodinated with 131I with a yield of practically 100 %. According to scintigraphy studies, 131I-DMANPER was completely accumulated in the stomach in 30 min. In the biodistributional data for 131I-DMANPER in rats, a significant amount of activity is seen in the stomach between 30-60 min. It can be concluded that 131I-DMANPER may be an alternative imaging agent like N-(2,6- diisopropylphenyl)-N`-(4-pyridyl)-perylene-3,4,9,10-tetracarboxylic diimide (PYPER) to be a potential agent for diagnosis and perhaps therapy of stomach cancer.